Myotwin

Myotwin operates at the intersection of rare disease, neuromuscular disorders, and therapeutics, offering a sophisticated preclinical testing platform for cardiac drug development. The company's unique value proposition lies in its 'trinity measurement' system, which simultaneously captures electrophysiology, calcium dynamics, and contractile force/stiffness from a single 3D human heart tissue model. This integrated, human-relevant data aims to address the high failure rates in cardiac drug development by providing more predictive insights earlier in the pipeline, potentially reducing reliance on animal models. Myotwin's service-based model targets pharmaceutical and biotech companies seeking to improve the predictability of their cardiac efficacy and safety studies.

Integrated platform combining 3D human iPSC-derived engineered heart tissues, proprietary hardware for simultaneous multiparametric measurement (electrophysiology, calcium dynamics, contraction force/stiffness), and AI-driven digital analysis to create predictive models for drug efficacy and toxicity.

Myotwin competes in the growing market for human iPSC-based cardiac models and microphysiological systems. Competitors include other specialized startups (e.g., Valo Health's Organoid platform, Novoheart), and larger CROs developing similar capabilities. Myotwin's differentiator is its integrated, simultaneous measurement of three key cardiac parameters plus stiffness on a single tissue.